Diabetes & Endocrinology Clinical Trials Update: Week 17, 2026

Published April 24, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

This Phase 3 trial is testing MET097, a once-weekly injectable medication, for adults who have overweight or obesity. If this treatment works well and is safe, it could offer a new option to help people manage their weight and related health problems. The study is recruiting participants in several countries and will continue for about 84 weeks, aiming to provide clear information on how MET097 may support long-term weight control.

A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

This large Phase 3 study evaluated semaglutide injections for weight loss in people living with obesity. More than 1400 participants took part across multiple countries, and the trial has now finished with results available. Semaglutide may offer an effective way to lose weight when combined with lifestyle changes, providing an additional tool to improve health for those struggling with excess weight.

Tirzepatide Use in People With Obesity and Type 1 Diabetes

This Phase 4 study is exploring the use of tirzepatide to help manage weight in people who have both type 1 diabetes and obesity. Since options are limited for this group, finding a safe and effective treatment could greatly improve health and quality of life. The trial is currently recruiting participants in Kuwait, and its findings may guide future treatment approaches.

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

This Phase 3 trial is focused on young patients, testing semaglutide injections to support weight loss in children and teenagers with overweight or obesity. Conducted across multiple countries, the study is active but not recruiting and will continue for about 2.5 years. Positive results could lead to new treatment options designed specifically for younger individuals facing weight challenges.

Integrating Care for Hypertension-Diabetes MULTImorbidity in Guatemala Through HEARTS Implementation

This study looks at a care program called HEARTS, designed to help adults managing both high blood pressure and type 2 diabetes. The goal is to improve how treatment is coordinated and make medicines easier to access in primary care clinics. The program is being tested over 12 months in Guatemala and could offer a way to better support people living with these common and often connected conditions.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.